Relmada Therapeutics Stock Forum

$SPDR S&P Biotech ETF(XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

follow for nightly watchlist
$ACM Research(ACMR.US)$ $Applied DNA Sciences(APDN.US)$ $Corbus Pharmaceuticals(CRBP.US)$ $Digital World Acquisition Corp(DWAC.US)$ $FedNat(FNHC.US)$ $IMARA(IMRA.US)$ $Laser Photonics(LASE.US)$ $NextEra Energy(NEE.US)$ $Relmada Therapeutics(RLMD.US)$ $Senti Biosciences(SNTI.US)$ $Visa(V.US)$ $Financial Select Sector SPDR Fund(XLF.US)$

Gapping up
In reaction to earnings/guidance:
• $Constellation Energy(CEG.US)$ +8.2%, $Walgreens Boots Alliance(WBA.US)$ +6.8%, $QuidelOrtho(QDEL.US)$ +6.7% (guides Q3 revs well above consensus), $Domino's Pizza(DPZ.US)$ +5.9%, $Delta Air Lines(DAL.US)$ +4.2%, $Commercial Metals(CMC.US)$ +3.5%, $Victoria's Secret(VSCO.US)$ +3.3%, $Taiwan Semiconductor(TSM.US)$ +2.6%
Other news:
• $Axsome Therapeutics(AXSM.US)$ +12.2% (trading h...

Gapping up
• $Melco Resorts and Entertainment(MLCO.US)$ +11.1% (China will allow Macau tour groups for first time in 3 years, according to Reuters)
• $Cohn Robbins(CRHC.US)$ +8% (Cohn Robbins Holdings Corp, and Allwyn agree not to proceed with business combination)
• $Las Vegas Sands(LVS.US)$ +6.7% (China will allow Macau tour groups for first time in 3 years, according to Reuters)
• $Chicken Soup for the Soul Entertainment(CSSE.US)$...

$Relmada Therapeutics(RLMD.US)$ $Denali Therapeutics(DNLI.US)$ $Tango Therapeutics(TNGX.US)$ $Goldman Sachs(GS.US)$ Goldman Sachs announced the latest list of potential acquisitions in the biopharmaceutical sector. Relmada, Denali and Tango have the most potential acquisition opportunities of the nine newly listed companies, Goldman sachs said. Relmada could trade at $115 a share, a 512% premium to its current price; Denali could trade at $166 a share, a 283% premium to its current price; Tango is likely to trade at $43.40 a share, a 295% premium to its current share price. The health care company with the biggest premium of the 24 companies listed is $uniQure NV(QURE.US)$, which Goldman estimates could trade at $174 a share, a 516% premium to its current price.